The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma.
Martin Bendszus
No relevant relationships to disclose
Jürgen Debus
No relevant relationships to disclose
Wolfgang Wick
Consultant or Advisory Role - Antisense Pharma; Magforce; Merck Serono (U); Merck Sharp & Dohme; Roche/Genentech
Honoraria - Medac; Merck Serono; Roche/Genentech
Research Funding - Apogenix; Lilly; Merck Sharp & Dohme
Grigory Kobyakov
No relevant relationships to disclose
Tobias Martens
No relevant relationships to disclose
Oliver Heese
No relevant relationships to disclose
Josef Pichler
No relevant relationships to disclose
Roger Stupp
No relevant relationships to disclose
Claudia Kunz
Employment or Leadership Position - Apogenix
Harald Fricke
Employment or Leadership Position - Apogenix